Multiple pioneering cancer research studies have unveiled promising therapeutic targets and treatment strategies. The University of Pittsburgh identified lncRNA EPIC1 as a driver of immune evasion in triple-negative breast cancer that suppresses type I interferon responses, enhancing resistance to PD-1 inhibitors. Meanwhile, Hospital del Mar Research Institute revealed a combination approach augmenting chemo-immunotherapy efficacy in small-cell lung cancer by targeting MET pathways. Additionally, a ready-made KRAS mutation vaccine elicited robust immune responses in pancreatic and colorectal cancer patients, potentially broadening immunotherapy options against challenging oncogenic drivers.